MedTrace Logo

Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis

NCT01925768 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2020-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.

Conditions

Interventions

DRUG

Apremilast 30 mg

30mg of Apremilast will be orally administered twice daily for 104 weeks

DRUG

Placebo

Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-04
Primary Completion
2015-02-25
Completion
2016-11-17

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Estonia
  • Hungary
  • New Zealand
  • Romania
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01925768 on ClinicalTrials.gov